Evaluation of Malondialdehyde (MDA) in type 2 diabetic Patients with Coronary Artery Disease (CAD)

Plasma Malondialdehyde and Risk of New-Onset Diabetes after Transplantation in Renal Transplant Recipients: A Prospective Cohort Study

“…The higher the intraindividual day-to-day variation is, the greater one would expect the benefit of repeated measurement for prediction of outcomes [40,41]. Next, although MDA has been the most commonly used OS biomarker in studies regarding glucose metabolism [9,10], further studies may want to account for other OS biomarkers to further validate our findings. Finally, the observational nature of this study makes it difficult to discern whether high levels of MDA are protective against NODAT or merely a marker of lower risk for NODAT; and, as with any observational study, residual confounding may have existed despite the substantial number of potentially confounding factors for which we adjusted, including well identified risk factors for NODAT.…”

“…Controversy may arise from data that has shown higher plasma MDA concentration in patients with diabetes mellitus than in healthy controls [8], and in patients who develop diabetes-related complications than in those without them [9]. However, it is known that ROS—as intracellular messengers—can generate opposite cellular effects.…”

“…LDL cholesterol was calculated by using the Friedewald equation; estimated glomerular filtration rate (eGFR) by the serum creatinine based Chronic Kidney Disease EPIdemiology collaboration equation (CKD-EPI) [26]; and the cumulative dose of prednisolone as the sum of the maintenance dose of prednisolone from transplantation until baseline. Plasma MDA concentration was chosen as the biomarker of OS because it has been used before in studies regarding pathologies of the glucose metabolism [8,9]; it was measured by high-performance liquid chromatography with a photodiode array detector as described by Faizan et al to improve the sensitivity offered by spectrophotometrically methods [27].…”

“…Oxidative stress (OS) is a factor that in different studies has been linked with both physiological response to insulin and pathophysiological mechanisms of, e.g., diabetes mellitus; it is also known to be enhanced in RTR when compared to general population [6]. Higher levels of OS biomarkers, e.g., MDA [7], have been found in patients with established diabetes mellitus compared to healthy controls [8], and in patients with diabetes-associated complications compared to patients with noncomplicated diabetes [9]. However, a developing body of evidence has linked oxidative species with insulin signaling [10,11,12,13], and it has been postulated that diabetes mellitus is—to a considerable extent—caused by a failure of the organism to create enough oxidative redox potential [14].…”

The Correlation between Malondialdehyde and Nerve Growth Factor Serum Level with Diabetic Peripheral Neuropathy Score

“…Bhutia (2011) and Jalees (2017) found that the MDA serum level was significantly elevated in patients with diabetes compared to those in normal subjects [14], [15]. Zavar-Reza (2014) observed significant increased MDA serum level in T2DM patients with complications [16]. Increased MDA serum level can be explained by increasing oxidative stress in diabetic patients.…”